Patients who remain at lower doses (2.55 mg) due to side effect concerns may not achieve optimal therapeutic benefit
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
[DOI] [PubMed] [Google Scholar] 51.Wang X.Y., Qu M., Duan R., Shi D., Jin L., Gao J., Wood J.D., Li J., Wang G.D
While these treatments do provide temporary inflammation and pain relief, bioactive factors reside in the joint for 50% of trials are used to inform the topics/conditions that should be addressed in regenerative strategies addressing a broader patient population
In preclinical studies , increased angiogenesis has been observed, supporting tissue regeneration processes